Cargando…

Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro

PURPOSE: Linezolid (LZD) and pretomanid (PA-824) are promising candidates in regimens for the treatment of drug-resistant tuberculosis. However, research on LZD and PA-824 dual drug-resistant (LPDR) strains is rarely reported. This study aimed to investigate the genotypic and virulence characteristi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Minghao, Fu, Lei, Wang, Bin, Xu, Jian, Guo, Shaochen, Zhao, Jiaojie, Li, Yuanyuan, Chen, Xiaoyou, Lu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297343/ https://www.ncbi.nlm.nih.gov/pubmed/32606825 http://dx.doi.org/10.2147/IDR.S257145

Ejemplares similares

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models
por: Zheng, Luyao, et al.
Publicado: (2023)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme?
por: Bharadwaj, Renu
Publicado: (2021)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus
por: Negatu, Dereje A., et al.
Publicado: (2023)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
por: Zhang, Peize, et al.
Publicado: (2022)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
por: Li, Hanbin, et al.
Publicado: (2019)

An Intensified Regimen Containing Linezolid Could Improve Treatment Response in Mycobacterium abscessus Lung Disease
por: Li, Hua, et al.
Publicado: (2019)

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis
por: Zhang, Lei, et al.
Publicado: (2023)

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
por: Lyons, Michael A.
Publicado: (2021)

Linezolid resistance in Mycobacterium tuberculosis isolates at a tertiary care centre in Mumbai, India
por: Nambiar, Remya, et al.
Publicado: (2021)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
por: Azimi, Taher, et al.
Publicado: (2022)

Pathogenicity and virulence of Mycobacterium tuberculosis
por: Rahlwes, Kathryn C., et al.
Publicado: (2023)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021)

Rv2577 of Mycobacterium tuberculosis Is a Virulence Factor With Dual Phosphatase and Phosphodiesterase Functions
por: Forrellad, Marina Andrea, et al.
Publicado: (2020)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow
por: Ushtanit, Anastasia, et al.
Publicado: (2021)

Virulence factors of the Mycobacterium tuberculosis complex
por: Forrellad, Marina A., et al.
Publicado: (2013)

Linezolid for drug‐resistant pulmonary tuberculosis
por: Singh, Bhagteshwar, et al.
Publicado: (2019)

Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis
por: Ismail, N., et al.
Publicado: (2018)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
por: Stancil, Stephani L, et al.
Publicado: (2021)

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
por: Bruning-Barry, Rebecca, et al.
Publicado: (2022)

Short and Efficient Synthesis of the Antituberculosis Agent Pretomanid from (R)-Glycidol
por: Lucas, Tobias, et al.
Publicado: (2023)

Comparative Proteomic Analyses of Avirulent, Virulent, and Clinical Strains of Mycobacterium tuberculosis Identify Strain-specific Patterns
por: Jhingan, Gagan Deep, et al.
Publicado: (2016)

Contrasting Transcriptional Responses of a Virulent and an Attenuated Strain of Mycobacterium tuberculosis Infecting Macrophages
por: Li, Alice H., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ojro1af36d2niu2tqr4dj897pv